The short version of cjc-1295 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-13 and is reviewed periodically as new material appears.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Counter-Strike Online is a free-to-play spin-off available in much of eastern Asia. It was developed by Nexon, with oversight from Valve. It uses a micropayment model that is managed by a custom version of the Steam back-end. Announced in 2012 and aimed at the Asian gaming market, a sequel titled Counter-Strike Online 2 was developed by Nexon on the Source game engine and released in 2013.
Cannabidiol has been used by professional and amateur athletes across disciplines and countries, with the World Anti-Doping Agency removing CBD from its banned substances list. The United States Anti-Doping Agency and United Kingdom-Anti-Doping Agency do not have anti-CBD policies, with the latter stating that, "CBD is not currently listed on the World Anti-Doping Agency Prohibited List. As a result, it is permitted to use in sport, though the intended benefits are unclear and not backed by clinical evidence. All other cannabinoids (including but not limited to cannabis, hashish, marijuana, and THC) are prohibited in-competition. The intention of the regulations is to prohibit cannabinoids that activate the same receptors in the brain as activated by THC." In 2019, the cannabis manufacturer Canopy Growth acquired majority ownership of BioSteel Sports Nutrition, which is developing CBD products under endorsement by numerous professional athletes. The National Hockey League Alumni Association began a project with Canopy Growth to determine if CBD or other cannabis products might improve neurological symptoms and quality of life in head-injured players. Some sports leagues have announced sponsorships with CBD companies, such as Major League Baseball (Charlotte's Web) and Ultimate Fighting Championship (Love Hemp). Numerous professional athletes use CBD, primarily for treating pain.
Record league victory: 9–0 v Loughborough, Second Division, 28 January 1899 v Accrington Stanley (away), Third Division North, 3 February 1934 Record cup victory: 6–0 v Blackpool, FA Cup first round, 20 January 1910 Record league defeat: 9–0 v Notts County, Second Division, 19 January 1927 Record cup defeat: 8–1 v Derby County, FA Cup first round, 30 January 1897 7–0 v Manchester United, EFL Cup third round, 17 September 2024 Most appearances: Barry Murphy, 569 Most goals scored for the club: Ernie Hine, 131 Most league goals scored in a season: Cecil McCormack, 33, 1950–51 Second Division Most international caps: Gerry Taggart, 35, Northern Ireland Record transfer fee received: £5,000,000 from Swansea City for Alfie Mawson (2017) Record transfer fee paid: £1,500,000 to Partizan Belgrade for Georgi Hristov (1997) and £1,500,000 to QPR for Mike Sheron (1999) Record attendance: 40,255 v Stoke City, FA Cup fifth round, 15 February 1936 Youngest ever Football League player: Reuben Noble-Lazarus, 15 years and 45 days Oldest player: Mike Pollitt, 41 years, 5 months and 30 days Most goals scored in a single game: 5; Frank Eaton v South Shields, 1927 Peter Cunningham v Darlington, 1933 Beaumont Asquith v Darlington, 1938 Cecil McCormack v Luton Town, 1950 Barnsley have spent more seasons and played more games at the second level of English football than any other team.
== Function == Dietary copper enters the bloodstream primarily in its oxidized Cu(II) form. Once absorbed, Cu(II) is taken up by the hCTR1, which mediates its cellular import. At the extracellular face, the flexible N-termini extends outward and captures Cu(II) from the blood carrier protein, after that it reduces Cu(II) to Cu(I) state and preserves the reduced Cu(I) oxidation state. The extracellular domain of hCTR1 holds both Cu(II) and Cu(I) binding sites: 1MDHxHH and 22HHH, serve as two Cu(II) binding sites; 7MxMxxM and 41MMMxM, comprise the first Cu(I) binding sites in the extracellular domain of hCTR1. The extracellular hCTR1 domain is also characterized by two glycosylation sites, N15 and T27. The transmembrane domain of hCTR1 is characterized by 150MxxxM and 167GxxxG motifs. In the second transmembrane helix, M150 and M154 are considered as Cu(I)-binding residues. There are two methionine triads lining the pore, and these methionine rings have soft sulfur ligands and create the "selectivity filter" for Cu(I), that excludes harder ions such as Ca(II). The hCTR1 C-terminal domain controls the distribution of Cu(I), it plays a role in copper trafficking and regulation. It interacts with metallochaperones and with the of the 188HCH motif transfers the Cu(I) ion to Atox1. Althogether hCTR1 operates as a dynamic, adaptable transporter, delicately balancing the flexibility and selectivity of copper ions.
Sources: en.wikipedia.org
=== Vaccinations === People with RA have an increased risk of infections and mortality, and recommended vaccinations can reduce these risks. The inactivated influenza vaccine should be received annually. The pneumococcal vaccine should be administered twice for people under the age 65 and once for those over 65. Lastly, the live-attenuated zoster vaccine should be administered once after the age 60, but is not recommended in people on a tumor necrosis factor alpha blocker.
According to Sagan, the first civilization with which humanity would come into contact could be between "1.5 J" and "1.8 K"; a galactic supercivilization would be at the "3 Q" stage, while a federation of galaxies could be at the "4 Z" stage. The information and energy axes are not strictly interdependent, so even a level Z civilization would not have to be Kardashev Type III. Sagan believed that no civilization had yet reached level Z, speculating that so much unique information would exceed that of all the intelligent species in a galactic supercluster, and observing that the universe is not old enough to exchange information effectively over large distances. In 2017, the total amount of information generated on the internet was 26 zettabytes (with an estimated 120 zettabytes in 2023), equivalent to 0.73 R/S on Sagan's combined scale.
== Treatment == There is no direct cure for Hypermobility Spectrum Disorder, but its symptoms can be treated. Physiotherapy, particularly exercise, is the main treatment for the condition, although there is only limited evidence for its effectiveness.
== Signs and symptoms == ED is characterized by the persistent or recurring inability to achieve or maintain an erection of the penis with sufficient rigidity and duration for satisfactory sexual activity. It is defined as the "persistent or recurrent inability to achieve and maintain a penile erection of sufficient rigidity to permit satisfactory sexual activity for at least 3 months."
=== Possible Paleocene survivors === Non-avian dinosaur remains have occasionally been found above the K-Pg boundary. In 2000, Spencer Lucas and colleagues reported the discovery of a single hadrosaur right femur in the San Juan Basin of New Mexico, and described it as evidence of Paleocene dinosaurs. The rock unit in which the bone was discovered has been dated to the early Paleocene epoch, approximately 64.8 million years ago. If the bone was not re-deposited by weathering action, it would provide evidence that some dinosaur populations survived at least half a million years into the Cenozoic. Other evidence includes the presence of dinosaur remains in the Hell Creek Formation up to 1.3 m (4.3 ft) above the Cretaceous–Paleogene boundary, representing 40,000 years of elapsed time. This has been used to support the view that the K-Pg extinction was gradual. However, these supposed Paleocene dinosaurs are considered by many other researchers to be reworked, that is, washed out of their original locations and then reburied in younger sediments. The age estimates have also been considered unreliable.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.